Study of Fremanezumab in Patients With Interstitial Cystitis-Bladder Pain Syndrome
- Study Title
- A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome
- Teva Identifier
- TV48125-CNS-20022
- ClinicalTrials.gov Identifier
- NCT04447729
- Study Status
- Withdrawn
- Trial Condition(s)
- Interstitial Cystitis
- Interventions
- Drug: fremanezumab
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female
- Age group
- Adult, Older Adult
- Age Range
- 18 Years and older
- Trial Duration
- October 15, 2020 - February 10, 2022
- Phase
- Phase 2
